KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) Long-Term Debt Issuances (2016 - 2026)

AbbVie has reported Long-Term Debt Issuances over the past 7 years, most recently at $4.0 billion for Q1 2025.

  • Quarterly Long-Term Debt Issuances fell 73.31% to $4.0 billion in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 billion through Dec 2025, down 76.45% year-over-year, with the annual reading at $4.0 billion for FY2025, 76.45% down from the prior year.
  • Long-Term Debt Issuances was $4.0 billion for Q1 2025 at AbbVie, up from $2.0 billion in the prior quarter.
  • Over five years, Long-Term Debt Issuances peaked at $15.0 billion in Q1 2024 and troughed at $1.0 billion in Q3 2021.
  • The 4-year median for Long-Term Debt Issuances is $2.0 billion (2022), against an average of $4.8 billion.
  • The largest YoY upside for Long-Term Debt Issuances was 73.31% in 2025 against a maximum downside of 73.31% in 2025.
  • A 4-year view of Long-Term Debt Issuances shows it stood at $1.0 billion in 2021, then skyrocketed by 100.0% to $2.0 billion in 2022, then changed by 0.0% to $2.0 billion in 2024, then soared by 99.7% to $4.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Long-Term Debt Issuances are $4.0 billion (Q1 2025), $2.0 billion (Q4 2024), and $15.0 billion (Q1 2024).